<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130818</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG0492-CL-101</org_study_id>
    <nct_id>NCT01130818</nct_id>
  </id_info>
  <brief_title>First-in-Human Single Ascending Dose of GLPG0492</brief_title>
  <official_title>Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of GLPG0492 in Healthy Subjects and Open Relative Bioavailability Study of Oral Solution Versus Solid Formulation, Fasted and Fed, in Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD)
      oral dose of GLPG0492 compared to placebo in healthy subjects.

      Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0492 after single oral
      administration will be evaluated, and, if applicable, the maximum tolerated dose determined.
      Oral bioavailability (solution vs solid capsule fasting or fed) is evaluated in healthy
      elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single ascending doses in healthy young and elderly subjects.</measure>
    <time_frame>up to 10 days postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single oral doses (solution) in young and elderly subjects.</measure>
    <time_frame>up to 10 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine oral bioavailability of GLPG0492 given to elderly subjects as oral solution or solid dosage form with or without food.</measure>
    <time_frame>up to 10 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the maximum tolerated dose in young subjects.</measure>
    <time_frame>Up to 10 days postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose, oral solution, 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose, capsules (fasting)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose, capsules (fed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0492</intervention_name>
    <description>single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single dose, oral solution</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0492</intervention_name>
    <description>single dose, solid formulation, 50 mg (2*25 mg/capsule), fasting</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0492</intervention_name>
    <description>single dose, solid formulation, 50 mg (2*25 mg/capsule), after high fat breakfast</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male, age 18-50 years (young subjects) OR ≥60 years (elderly subjects)

          -  BMI between 18-30 kg/m², inclusive

          -  non-smoker

        Exclusion Criteria:

          -  elevated PSA

          -  drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Namour, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sofie Mesens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Stuivenberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Senior Vice President Development</name_title>
    <organization>Galapagos NV</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Bioavailability (solid vs solution, fasting vs fed)</keyword>
  <keyword>Young healthy subjects</keyword>
  <keyword>Elderly healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

